ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences.
2025 Stifel Healthcare Conference
Fireside Chat: Thursday, November 13, 9:20am EST
New York, NY
Piper Sander 37th Annual Healthcare Conference
Fireside Chat: Thursday, December 4, 10:00am EST
New York, NY
To access the live webcasts or subsequent archived recordings of the presentation and fireside chat, please visit the .
About ImageneBio, Inc.
ImageneBio is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The company’s lead asset, IMG-007, is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of IMG-007 in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. For more information, please visit .
Investor and Media Contact:
